浙江奥翔药业股份有限公司 章 程 二○二三年十一月 1 | 第一章 总则 3 | | | --- | --- | | 第二章 经营宗旨和范围 4 | | | 第三章 股份 4 | | | 第一节 | 股份发行 4 | | 第二节 | 股份增减和回购 6 | | 第三节 | 股份转让 8 | | 第四章 股东和股东大会 9 | | | 第一节 | 股东 9 | | 第二节 | 股东大会的一般规定 12 | | 第三节 | 股东大会的召集 17 | | 第四节 | 股东大会的提案与通知 19 | | 第五节 | 股东大会的召开 21 | | 第六节 | 股东大会的表决和决议 24 | | 第五章 董事会 31 | | | 第一节 | 董事 31 | | 第二节 | 董事会 36 | | 第六章 经理及其他高级管理人员 41 | | | 第七章 监事会 45 | | | 第一节 | 监事 45 | | 第二节 | 监事会 46 | | 第八章 财务会计制度、利润分配和审计 48 | | | 第一节 | 财务会计制度 48 | | 第二节 | 内部审计 54 | | 第三节 | 会计师事务所的聘任 54 | | 第九 ...

浙江奥翔药业股份有限公司 关于修订《公司章程》及部分内部管理制度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：603229 证券简称：奥翔药业 公告编号：2023-049 | 第一百一十一条 公司董事会设立战略委员会、审计委员 | 第一百一十一条 公司董事会设立战略委员会、审计委员 | | --- | --- | | 会、提名委员会、薪酬与考核委员会。专门委员会成员全部由 | 会、提名委员会、薪酬与考核委员会。专门委员会成员全部由董 | | 董事组成，其中审计委员会、提名委员会、薪酬与考核委员会 | 事组成，其中审计委员会、提名委员会、薪酬与考核委员会中独 | | 中独立董事应占多数并担任召集人，审计委员会中至少应有一 | 立董事应过半数并担任召集人，审计委员会的成员应当为不在上 | | 名独立董事是会计专业人士且担任召集人。 | 市公司担任高级管理人员的董事，召集人应当为会计专业人士。 | | …… | …… | | 第一百二十六条 公司设经理 1 名，由董事会聘任或解聘。 | 第一百二十六条 公司设经理 ...

证券代码：603229 证券简称：奥翔药业 公告编号：2023-047 浙江奥翔药业股份有限公司 第三届监事会第十七次会议决议公告 浙江奥翔药业股份有限公司（以下简称"公司"）第三届监事会第十七次会 议于 2023 年 11 月 28 日在浙江省化学原料药基地临海园区东海第四大道 5 号公 司新办公楼一楼会议室以现场的方式召开。会议通知已于 2023 年 11 月 23 日以 专人送达或电子邮件方式送交公司全体监事。本次会议应参加监事 3 人，实际参 加监事 3 人，会议由监事会主席徐海燕女士主持。会议的通知、召集、召开和表 决程序符合《中华人民共和国公司法》《公司章程》等有关法律、法规的规定。 二、监事会会议审议情况 经全体监事认真审议并表决，一致通过了如下议案： （一）审议通过《关于监事会换届选举的议案》 鉴于公司第三届监事会任期将于 2023 年 12 月 13 日届满，根据《公司法》 《公司章程》等有关规定，需进行监事会换届选举。第四届监事会成员由 3 名监 事组成，经监事会提名，余官能先生、代春光先生为公司第四届监事会非职工监 事候选人。与职工代表大会选举产生的职工代表监事徐海燕女士共同组成公司第 ...

Financial Performance - The company's revenue for Q3 2023 was CNY 202,946,435.18, representing a year-over-year increase of 3.25%[4] - Net profit attributable to shareholders for Q3 2023 was CNY 65,140,884.49, up 20.51% compared to the same period last year[4] - The net profit after deducting non-recurring gains and losses for Q3 2023 was CNY 59,212,971.21, reflecting a 23.58% increase year-over-year[4] - Basic earnings per share for Q3 2023 was CNY 0.11, an increase of 22.22% year-over-year[4] - Total operating revenue for the first three quarters of 2023 reached ¥671,662,047.60, an increase of 16.2% compared to ¥577,913,726.42 in the same period of 2022[16] - Net profit for the first three quarters of 2023 was ¥225,337,632.82, representing a 27.2% increase from ¥177,077,646.30 in the previous year[17] - Earnings per share for the first three quarters of 2023 were ¥0.38, compared to ¥0.31 in the same period of 2022, indicating a growth of 22.6%[17] Cash Flow - The net cash flow from operating activities for Q3 2023 was negative CNY 30,176,859.84, a decrease of 134.45% compared to the previous year[4] - The net cash inflow from operating activities for Q3 2023 was CNY 10,286,467.01, a decrease of 90.9% compared to CNY 112,871,999.25 in Q3 2022[20] - The total cash inflow from operating activities was CNY 708,900,804.99, compared to CNY 655,754,734.60 in Q3 2022, reflecting a growth of 8.3%[20] - The total cash outflow from operating activities was CNY 698,614,337.98, an increase of 28.7% from CNY 542,882,735.35 in the previous year[20] - The company received tax refunds amounting to CNY 37,382,108.55, compared to CNY 24,846,283.94 in Q3 2022, indicating a growth of 50.2%[20] - The company reported a cash increase of CNY 388,052,554.78 for the quarter, compared to CNY 42,301,943.10 in Q3 2022, marking a significant improvement[21] Assets and Liabilities - Total assets at the end of Q3 2023 amounted to CNY 2,973,290,511.32, a 28.42% increase from the end of the previous year[5] - Shareholders' equity attributable to the parent company reached CNY 2,113,049,904.50, up 44.62% compared to the end of the previous year[5] - The total liabilities as of the end of the third quarter of 2023 were ¥860,240,606.82, slightly up from ¥854,189,668.14 in the previous year[16] - The company's total current liabilities increased to RMB 1,000,000,000, with short-term borrowings rising to RMB 250,279,855.18 from RMB 160,120,228.06, a growth of approximately 56.4%[12] - Non-current assets totaled RMB 1,260,158,649.11, up from RMB 1,178,625,030.82, indicating an increase of about 6.9%[12] Investments and Expenses - Research and development expenses for the first three quarters of 2023 totaled ¥73,686,399.20, up from ¥52,596,549.73 in the same period of 2022, marking a significant increase of 40%[16] - Total operating costs for the first three quarters of 2023 were ¥419,225,427.62, up from ¥382,244,257.88 in 2022, reflecting a rise of 9.7%[16] Other Financial Metrics - The weighted average return on net assets for Q3 2023 was 3.02%, a decrease of 0.91 percentage points from the previous year[5] - Non-recurring gains and losses for Q3 2023 totaled CNY 5,927,913.28, with a year-to-date total of CNY 12,892,197.50[7] - The company reported a financial income of ¥22,091,667.01 for the first three quarters of 2023, compared to ¥4,397,074.29 in the same period of 2022, showing a substantial increase[16] - Deferred income tax liabilities increased to ¥13,018,281.46 from ¥12,514,059.91 year-over-year, reflecting a growth of 4%[16] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 32,617[9]

证券代码：603229 证券简称：奥翔药业 公告编号：2023-045 浙江奥翔药业股份有限公司 关于召开 2023 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 浙江奥翔药业股份有限公司（以下简称"公司"）已于 2023 年 10 月 28 日 发布公司 2023 年第三季度报告，为便于广大投资者更全面深入地了解公司 2023 年前三季度经营成果、财务状况，公司计划于 2023 年 11 月 20 日下午 15：00-16： 00 举行 2023 年第三季度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2023 年前三季度的经 营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的 范围内就投资者普遍关注的问题进行回答。 二、说明会召开时间、地点 （一）会议召开时间：2023 年 11 月 20 日（星期一）下午 15：00-16：00 重要内容提示： 会议召开时间：2023 年 11 月 20 日（星期一）下午 15： ...

Financial Performance - The company's operating revenue for the first half of 2023 reached ¥468,715,612.42, representing a 22.91% increase compared to ¥381,360,543.87 in the same period last year[19]. - The net profit attributable to shareholders of the listed company was ¥160,196,748.33, up 30.22% from ¥123,023,476.54 in the previous year[19]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥153,232,464.11, reflecting a 30.68% increase from ¥117,259,671.95 year-on-year[19]. - The net cash flow from operating activities was ¥40,463,326.85, a significant increase of 60.03% compared to ¥25,285,282.43 in the same period last year[19]. - The net assets attributable to shareholders at the end of the reporting period were ¥2,095,249,484.09, a 43.40% increase from ¥1,461,140,520.64 at the end of the previous year[19]. - Total assets increased by 30.14% to ¥3,013,263,821.39 from ¥2,315,330,188.78 at the end of the previous year[19]. - Basic earnings per share for the first half of 2023 increased to CNY 0.27, up 22.73% from CNY 0.22 in the same period last year[20]. - Diluted earnings per share also rose to CNY 0.27, reflecting a 22.73% increase compared to the previous year[20]. Research and Development - The company has established a research and development team of over 200 members, focusing on various aspects of drug development and production optimization[44]. - The company invested 47.90 million yuan in R&D, representing 10.22% of operating revenue, to enhance product development capabilities[52]. - Research and development expenses increased by 66.52% to CNY 47,902,225.02, up from CNY 28,767,285.27, primarily due to increased employee compensation and design testing costs[56][57]. - The company is actively developing a new drug, Brozospin Sodium, for ischemic stroke, with Phase I studies completed and Phase II trials concluded[46]. - The company is developing a new Class 1 drug for the treatment of ischemic stroke, with Phase II clinical trials completed and awaiting Phase III[26]. Market and Industry Trends - The global pharmaceutical market size grew from $1,208.4 billion in 2017 to $1,401.2 billion in 2021, with a projected CAGR of 5.2% from 2021 to 2025, reaching $1,718.8 billion by 2025[31]. - The global CRO market size increased from $40.1 billion in 2014 to $71.9 billion in 2021, with a CAGR of 8.7%, and is expected to reach $95.2 billion in 2023[33]. - The global CDMO market size rose from $39.4 billion in 2017 to $63.2 billion in 2021, with a CAGR of 12.5%, projected to reach $124.3 billion by 2025[34]. - China's pharmaceutical market expanded from ¥1,430.4 billion in 2017 to ¥1,591.2 billion in 2021, with a CAGR of 2.7%, expected to reach ¥2,064.5 billion by 2025[36]. - The innovative drug market in China accounted for 59.5% of the overall pharmaceutical market in 2021, with a projected market size of ¥1,401 billion by 2025[37]. Environmental Compliance and Sustainability - The company has established a wastewater treatment system with a capacity of 600 tons per day and an organic waste gas RTO incineration device with a capacity of 38,000 cubic meters per hour[80]. - The company is classified as a key pollutant discharge unit by environmental protection authorities, indicating a focus on environmental compliance and sustainability[78]. - Environmental self-monitoring plans have been implemented, with third-party monitoring showing that all pollutant indicators meet discharge standards[84]. - The company has committed to avoiding competition with its own business in any other organizations controlled by its shareholders[87]. Financial Position and Capital Management - The total amount of guarantees provided by the company to subsidiaries during the reporting period was RMB 35,000.00 million[95]. - The total amount of guarantees, including those to subsidiaries, accounted for 16.70% of the company's net assets[95]. - The company approved a guarantee limit of up to RMB 60,000.00 million for its wholly-owned subsidiary Zhejiang Qizheng Pharmaceutical Co., Ltd.[95]. - The total number of shares increased to 423,620,992 after a non-public offering of 21,754,288 shares, representing 5.14% of the total share capital[100]. - The company distributed a cash dividend of CNY 0.112 per share, totaling CNY 47,445,551.10, and increased capital by 0.4 shares per existing share, resulting in a total of 593,069,389 shares post-distribution[147]. Operational Highlights - The CRO/CDMO/CMO business segment has gained recognition in the international market, becoming a strategic supplier for several large pharmaceutical companies[26]. - The company achieved operating revenue of 468.72 million yuan, a year-on-year increase of 22.91%[49]. - The CRO/CDMO/CMO business generated sales revenue of 229.86 million yuan, accounting for 49.04% of total operating revenue[49]. - The company has completed multiple series of raw materials and intermediates, ready for scale sales following patent expirations of target drugs[44]. - The company is focusing on expanding its customer base, particularly in Europe, the US, and Japan, to enhance sales proportions in these markets[52]. Risk Management - The company has not experienced any major safety production accidents as of the report date, but risks remain due to potential equipment and operational issues[73]. - The company’s export business is significantly impacted by exchange rate fluctuations, which can affect operating performance[73]. - The company has faced rising raw material prices, which have increased production costs and pressured profit margins[73]. Shareholder Information - The total number of ordinary shareholders as of the end of the reporting period is 32,249[105]. - The top shareholder, Zheng Zhiguo, holds 214,506,991 shares, representing 50.64% of the total shares[107]. - The total shares held by the top ten shareholders amount to 254,000,000 shares, which is approximately 61.12% of the total shares[107]. - The company has no preferred shareholders with restored voting rights as of the end of the reporting period[105]. Compliance and Governance - The company has not reported any violations or penalties involving its directors, supervisors, or senior management during the reporting period[92]. - There were no non-operating fund occupations by controlling shareholders or related parties during the reporting period[90]. - The company confirmed no major guarantees during the reporting period[91].

证券代码：603229 证券简称：奥翔药业 公告编号：2023-043 浙江奥翔药业股份有限公司 关于修订《公司章程》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 浙江奥翔药业股份有限公司（以下简称"公司"）于 2023 年 8 月 29 日召开 了第三届董事会第十九次会议，审议通过了《关于修订〈公司章程〉的议案》。 具体情况如下： 根据公司 2022 年年度股东大会审议通过的《关于 2022 年度利润分配及资本 公积金转增股本预案的议案》，公司以权益分派实施前的总股本 423,620,992 股 为基数，以资本公积金向全体股东每 10 股转增 4 股，共计转增 169,448,397 股。 本次转增完成后，公司总股本变更为 593,069,389 股，注册资本变更为 593,069,389.00 元。公司 2022 年年度权益分派已于 2023 年 7 月 12 日实施完毕。 针对上述情况，同时根据《中华人民共和国证券法》《中华人民共和国公司 法》《上市公司章程指引》等有关规定，拟对《公司章程》相关条款进行修订。 ...

证券代码：603229 证券简称：奥翔药业 公告编号：2023-041 浙江奥翔药业股份有限公司 第三届监事会第十五次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 浙江奥翔药业股份有限公司（以下简称"公司"）第三届监事会第十五次会 议于 2023 年 8 月 29 日在浙江省化学原料药基地临海园区东海第四大道 5 号公司 301 会议室以现场的方式召开。会议通知已于 2023 年 8 月 19 日以专人送达或电 子邮件方式送交公司全体监事。本次会议应参加监事 3 人，实际参加监事 3 人， 会议由监事会主席徐海燕女士主持。会议的通知、召集、召开和表决程序符合《中 华人民共和国公司法》《公司章程》等有关法律、法规的规定。 二、监事会会议审议情况 经全体监事认真审议并表决，一致通过了如下议案： （一）审议通过《关于公司 2023 年半年度报告及其摘要的议案》 监事会认为：公司 2023 年半年度报告的编制和审议程序符合相关法律、法 规、公司章程和公司内部管理制度的各项规定。2023 年半年度 ...

浙江奥翔药业股份有限公司 证券代码：603229 证券简称：奥翔药业 公告编号：2023-044 浙江奥翔药业股份有限公司（以下简称"公司"）已于 2023 年 8 月 30 日发 布公司 2023 年半年度报告，为便于广大投资者更全面深入地了解公司 2023 年半 年度经营成果、财务状况，公司计划于 2023 年 9 月 12 日下午 15:00-16: 30 举 行 2023 年半年度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以视频结合网络互动召开，公司将针对 2023 年半年度的 经营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许 的范围内就投资者普遍关注的问题进行回答。 二、说明会召开时间、地点 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2023 年 9 月 12 日(星期二) 下午 15:00-16:30 会议召开 地点：上海证券交易所上证路演中心（网址： http://roadsho ...

证券代码：603229 证券简称：奥翔药业 公告编号：2023-040 浙江奥翔药业股份有限公司 第三届董事会第十九次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 浙江奥翔药业股份有限公司（以下简称"公司"）第三届董事会第十九次会 议于 2023 年 8 月 29 日在浙江省化学原料药基地临海园区东海第四大道 5 号公司 301 会议室以现场与通讯相结合的方式召开。会议通知已于 2023 年 8 月 19 日以 专人送达或电子邮件方式送交公司全体董事。本次会议应参加董事 9 人，实际参 加董事 9 人，会议由公司董事长郑志国先生主持，公司全体监事及高级管理人员 列席了本次会议。会议的通知、召集、召开和表决程序符合《中华人民共和国公 司法》《公司章程》等有关法律、法规的规定。 二、董事会会议审议情况 经全体董事认真审议并表决，一致通过了如下议案： 具体内容详见上海证券交易所网站（www.sse.com.cn）、《上海证券报》《证 券时报》上刊登的《奥翔药业 2023 年半年度报告》和《奥翔 ...